Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a mid-stage clinical trial involving 141 patients. Lp(a) is a genetic risk factor for heart attacks,

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated 1.4 billion people worldwide, including 64 million people in the U.S.

On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a staggering 94% in a mid-stage clinical trial. The effects lasted for six months after just one or two injections, with no serious side effects reported.

Women tend to live healthier lives than men, but new research suggests that common risk factors for heart disease have twice the impact on women than on men. Experts explain why and share what you can do to protect your heart.

Inherited or genetic heart disorders, mostly known as Hypertrophic cardiomyopathy (HCM) in medical term, is a condition affecting the left ventricle, the main pumping chamber of the heart. This condition,

Eli Lilly (NYSE:LLY) released positive Phase 2 results for its small interfering RNA (siRNA) drug candidate lepodisiran on Sunday. The trial results showed 94% lower levels of a genetically inherited heart disease risk factor in adults with elevated risk taking the highest test dose of the drug candidate.

Key Takeaways A new drug lowered a heart risk factor, Lp(a), by 94% with one shotLp(a) affects an estimated 64 million Americans but is rarely testedLarge trials are underway to see if the drug can prevent heart attacks MONDAY,